ImCheck obtient 20,18 millions d’euros de financement public dans le cadre du plan France 2030
29. August 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck reçoit un financement non-dilutif significatif afin d’accélérer l’avancement de deux programmes innovants, dans le traitement des cancer et des maladies infectieuses, en ligne avec l’ambition...
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
29. August 2024 05:00 ET
|
ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030...
Bpifrance s’associe à Capgemini pour la création de sa Digital Factory de nouvelle génération
10. November 2023 02:30 ET
|
Capgemini SE
Relations presse Capgemini : Hélène Delannet Tel. : + 33 1 57 99 44 51 E-mail : helene.delannet@capgemini.comRelations presse Bpifrance : Juliette FontanillasTel. : +33 6 72 76 08 09 E-mail :...
Bpifrance partners with Capgemini for the creation of a next generation digital factory
10. November 2023 02:30 ET
|
Capgemini SE
Media Relations Capgemini: Hélène Delannet Tel.: +33 1 57 99 44 51 E-mail: helene.delannet@capgemini.comMedia Relations Bpifrance: Juliette FontanillasTel.: +33 6 72 76 08 09 E-mail:...
Diaccurate est soutenue par Bpifrance pour son Programme DIACC2020 portant sur le développement de nouveaux composés cytotoxiques conjugués à des anticorps thérapeutiques (ADCs)
05. Januar 2023 02:00 ET
|
DIACCURATE
La plateforme DIACC2020 ambitionne de mettre au point une nouvelle génération de composés cytotoxiques pouvant être conjugués à des anticorps thérapeutiquesElle s’appuie sur les propriétés uniques du...
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)
05. Januar 2023 02:00 ET
|
DIACCURATE
The DIACC2020 platform aims to develop a new generation of cytotoxic compounds to be conjugated to therapeutic antibodies The Program stems from the unique properties of its proprietary compound...
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
13. Juni 2022 01:00 ET
|
ImCheck Therapeutics SAS
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera...
ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
15. September 2020 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Announces Investment by BB Pureos Bioventuresto Close Series B Fundraising with Total of €54 million ($64 million) Marseille, France, September 15, 2020 – ImCheck Therapeutics today announced...
Innate Pharma obtient un financement public de 6,8M€ pour ses activités de recherche et développement dans la COVID-19
11. August 2020 01:00 ET
|
INNATE PHARMA
Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce avoir obtenu un financement de 6,8 M€ dans le cadre de l’appel à projet PSCP-COVID...
Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities
11. August 2020 01:00 ET
|
INNATE PHARMA
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the Company has obtained funding of €6.8M under the PSPC-COVID call for projects...